SIM0388 for fluid buildup in the abdomen from cancer
Part of Cancer clinical trials.
This trial tests a new drug, SIM0388, for people whose cancer has spread and caused fluid buildup in the belly. It aims to see if the drug is safe and can help reduce the fluid.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic solid tumor cancer that has been confirmed by biopsy or cell sample.
- Your cancer has not responded to at least one standard treatment, or you cannot have standard treatment.
- You have moderate or more fluid in the belly confirmed by ultrasound.
- You are age 18 or older.
- You are able to walk and care for yourself (ECOG score 0-2) and expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether an immune-blocking drug placed directly into the belly cavity can help people with cancer-caused fluid buildup (malignant ascites) from stomach, pancreas, or bile-duct cancers. It may help shrink the fluid and slow the illness, but you must meet specific safety and treatment-history requirements.
This early-stage trial tests a new drug (WSK-IM02) delivered directly into the space around your lungs or abdomen to treat fluid buildup caused by advanced cancer. The drug is designed to reduce this fluid and improve your symptoms and quality of life.
This trial tests three drugs (bevacizumab, serplulimab, and rmhTNF-NC) given together to treat fluid buildup in the belly caused by digestive system cancers. It’s for people whose ascites has not improved after standard treatments.
This trial tests a drug called liposomal irinotecan, given alone or with other medications, to treat fluid buildup in the belly caused by digestive system cancers. It's for people who have already tried standard treatments without success.
This trial tests a new drug called SIM0508, given alone or with another drug (olaparib), in people with advanced ovarian, prostate, breast, or pancreatic cancer. The goal is to see if it is safe and effective.
This early-phase trial tests an experimental drug called GK02 for people with advanced cancer who have fluid buildup in the belly (malignant ascites). The drug is given directly into the belly to try to reduce the fluid and control symptoms.
Hear when a new Malignant Ascites trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.